Sage Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Premium on marketable securities
Amortization of (discount) premium on marketable securities
Depreciation expense
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Collaboration receivable - related party
Other long-term assets
Right-of-use operating asset
Operating lease liabilities, current
Operating lease liabilities, non-current
Accounts payable
Accrued expenses and other liabilities
Net cash used in operating activities
Cash flows from investing activities
Proceeds from sales and maturities of marketable securities
Purchases of marketable securities
Purchases of property and equipment
Net cash provided by investing activities
Cash flows from financing activities
Proceeds from stock option exercises and employee stock purchase plan issuances
Payments of offering costs
Proceeds from public offerings of common stock, net of commissions and underwriting discounts
Payment of employee tax obligations related to vesting of restricted stock units
Proceeds from the sale of common stock under the Stock Purchase Agreement
Proceeds from the sale of common stock under the Stock Purchase Agreement - related party
Net cash provided by financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosure of non-cash operating activities
Right-of-use assets obtained in exchange for new operating lease liabilities
Purchases of property and equipment included in accounts payable
Lease asset de-recognized upon lease cancellation

Reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets
Cash and cash equivalents
Restricted cash
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows

Comments